Stocktoria
Opus Genetics, Inc. IRD
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2004-11-30
Opus Genetics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589,000 | $0 | $3.0M | — | — | — |
| R&D expense | — | — | — | — | — | — | $5.5M | $13.1M | $10.7M | $10.1M |
| Operating income | -$38.6M | -$62.1M | -$10.6M | $18.2M | -$22.7M | -$20.0M | -$4.2M | -$20.5M | -$17.4M | -$16.4M |
| Interest expense | — | — | $0 | $9,000 | $2,000 | $6.8M | $1.4M | — | — | — |
| Income tax | $0 | $0 | $12,000 | $315,000 | $0 | $0 | $0 | — | — | — |
| Net income | -$49.6M | -$57.5M | -$10.0M | $17.9M | -$56.7M | -$24.6M | -$6.2M | -$14.4M | -$25.3M | -$9.3M |
| EPS (diluted) | $-0.80 | $-2.15 | $-0.46 | $0.87 | $-3.82 | $-5.28 | — | — | — | — |
| Operating cash flow | -$35.3M | -$25.6M | -$1.1M | $14.3M | -$19.4M | -$6.8M | -$3.6M | -$18.8M | -$15.4M | -$13.2M |
| Free cash flow | — | — | — | — | — | -$6.8M | -$3.6M | — | — | — |
| Cash & equivalents | $45.1M | $30.3M | $50.5M | $42.6M | $24.5M | — | — | $8.7M | $8.9M | $11.6M |
| Total assets | $50.2M | $36.9M | $53.9M | $49.0M | $26.1M | $17.7M | $1.8M | $16.0M | $28.3M | $21.0M |
| Total liabilities | $34.9M | $11.3M | $4.0M | $2.8M | $3.9M | $31.1M | $9.3M | $5.5M | $11.5M | $4.0M |
| Shareholders' equity | $15.3M | $6.7M | $49.9M | $46.2M | $22.2M | -$13.5M | -$7.6M | -$1.7M | $16.8M | $17.1M |
Growth · year-over-year · Revenue CAGR 29.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +29.1% | -42.3% | -52.2% | +6665.7% | — | -100.0% | — | — | — | — |
| Net income growth | — | — | -155.8% | — | — | — | — | — | — | — |
| EPS growth | — | — | -152.9% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.